Indee Labs focuses on the development of microfluidic vortex shedding for rapidly and efficiently transfecting human primary immune cells with negligible perturbation. The team is focused on developing its core technology for short turnaround chimeric antigen receptor T cell (CAR-T) development and manufacturing.
BioMedTech Horizons Precision Medicine
Medical Device Fund
Minimum Viable Product
Jobs for NSW
Amy A. Twite, Katherine H.W.J. Lau, Moein N. Kashani, Craig Priest, Jorge Nieva, David Gottlieb, Ryan S. Pawell
Intracellular delivery of mRNA to human primary T cells with microfluidic vortex shedding
Indee Labs was founded on August 16, 2015 with a mission'mission to democratize gene-modified cell therapies' such as chimeric antigen receptor T cells (CAR-T). The team is developing a novel transfection technology that can rapidly and efficiently deliver a variety of genetic material (e.g., DNA, RNA, protein and/or various complexes) to human primary immune cells in seconds.